CDY’s midkine antibody shown to accelerate bone fracture healing

Published 24-JUN-2016 15:08 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Australian biotechnology company Cellmid Limited (ASX:CDY) has announced that its midkine (MK) antibody has been shown to accelerate the bone healing and formation process.

The study led by Dr Astrid Liedert at the Orthopedic Research and Biomechanics, University Medical Center Ulm, Germany is the first ever in showing CDY’s technology in action, a major milestone for the company.

The results were published in the esteemed British Journal of Pharmacology:

(Haffner-Luntzer M et al, Antagonizing Midkine Accelerates Fracture Healing in Mice by Enhanced Bone Formation in the Fractured Callus. Br J Pharmacol. doi: 10.1111/bph.13503. PMID: 27111560)

The study concluded that “Mdk-Ab treatment may be a potential novel therapeutic strategy to enhance fracture healing in patients with orthopedic complications such as delayed healing or non-union formation.”

The clinically significant results are a step forward for CDY in seeking to address the need in the bone fracture market, where up to 10% of all bone fractures result in delayed bone healing and even-union formation.

This is of great concern in the world’s increasing ageing population, where fractures often take an extended amount of time to heal. Placing great burden on the patient, health care system and care givers, highlighting the need for better therapies such as CDY’s MK antibodies.

Further to these latest promising results, CDY has filed a patent application to secure its IP in the application of its MK antibodies in bone therapy.

Today’s announcement contributes to positive data and promising results already gathered in relation to CDY’s MK antibodies treatment of chronic kidney disease.

MK has been shown to be an important early marker for diagnosing various diseases and is only evident in a disease context. Unlike many other forms of treatment, targeting MK is not expected to harm normal health tissue.

CDY plans to commercialise its MK antibody through wholly owned subsidiary Lyramid Limited, which is dedicated to developing drugs in treating various conditions targeting MK.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X